MAIA Biotechnology Inc. Total Liabilities
MAIA Biotechnology Inc. total liabilities. Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has total liabilities worth $7.56 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See MAIA Biotechnology Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of MAIA Biotechnology Inc. (2019–2025)
Total liabilities of MAIA Biotechnology Inc. from 2019 to 2025. This chart illustrates how MAIA Biotechnology Inc.'s total liabilities have evolved over time, based on quarterly financial data.
MAIA Biotechnology Inc. Competitors by Total Liabilities
The table below lists competitors of MAIA Biotechnology Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jinhui Shipping and Transportation Limited
OL:JIN
|
Norway | Nkr155.17 Million |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
USA | $2.49 Million |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
Taiwan | NT$77.78 Million |
|
Asetek A/S
F:A31
|
Germany | €35.78 Million |
|
Saunders International Ltd
AU:SND
|
Australia | AU$50.47 Million |
|
Wintergreen Acquisition Corp. Ordinary Shares
NASDAQ:WTG
|
USA | $132.00K |
|
Karel Elektronik Sanayi ve Ticaret AS
IS:KAREL
|
Turkey | TL10.98 Billion |
|
EXA E&C Inc
KQ:054940
|
Korea | ₩74.43 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down MAIA Biotechnology Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of MAIA Biotechnology Inc..
Liquidity & Leverage Metrics
MAIA Biotechnology Inc. Total Liabilities Ratios Explained
MAIA Biotechnology Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MAIA Biotechnology Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MAIA Biotechnology Inc. (2019–2025)
The table below shows the annual total liabilities of MAIA Biotechnology Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.33 Million | +12.39% |
| 2024-12-31 | $6.52 Million | -8.02% |
| 2023-12-31 | $7.09 Million | +101.73% |
| 2022-12-31 | $3.51 Million | +63.76% |
| 2021-12-31 | $2.15 Million | -9.18% |
| 2020-12-31 | $2.36 Million | +476.66% |
| 2019-12-31 | $409.74K | -- |
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illin… Read more